With $2B J&J Deal, FCA Proves It's Still The Anti-Fraud King

Law360, New York (November 04, 2013, 8:51 PM ET) -- The U.S. Department of Justice's $2.2 billion settlement with Johnson & Johnson shows that, despite the recent attention heaped on whistleblower provisions in Dodd-Frank and similar laws, the False Claims Act remains the federal government's weapon of choice in extracting gargantuan settlements from companies that have allegedly committed fraud.

Announced Monday morning, the agreement resolves FCA claims that Johnson & Johnson promoted the antipsychotic drug Risperdal and two other medications for off-label uses and paid kickbacks to physicians and a large pharmacy provider.

The settlement is one...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers